Thomas O Bergmeijer1, Gerrit Ja Vos1, Daniël Mf Claassens1, Paul Wa Janssen1, Remko Harms2, Richard van der Heide2, Folkert W Asselbergs3,4,5,6, Jurriën M Ten Berg1, Vera Hm Deneer7. 1. Department of Cardiology, St Antonius Hospital, 3435 CM, Nieuwegein, The Netherlands. 2. Department of Clinical Pharmacy, St Antonius Hospital, 3435 CM, Nieuwegein, The Netherlands. 3. Department of Cardiology, Division Heart & Lungs, UMC Utrecht, 3584 CX, Utrecht, The Netherlands. 4. Durrer Center for Cardiovascular Research, Netherlands Heart Institute, 3501 DG, Utrecht, The Netherlands. 5. Institute of Cardiovascular Science, Faculty of Population Health Sciences, University College London, WC1E, London, UK. 6. Farr Institute of Health Informatics Research & Institute of Health Informatics, University College London, WC1E, London, UK. 7. Department of Clinical Pharmacy, University Medical Center Utrecht, 3584 CX, Utrecht, The Netherlands.
Abstract
AIM: A tailored antiplatelet strategy based on CYP2C19 genotype may reduce atherothrombotic and bleeding events. We describe our experience with CYP2C19 genotyping, using on-site TaqMan or Spartan genotyping or shipment to a central laboratory. METHODOLOGY: Data from two ongoing projects were used: Popular Risk Score project (non-urgent percutaneous coronary intervention patients) and the Popular Genetics study (ST-segment elevation myocardial infarction patients). For both projects, the time to genotyping result was calculated. RESULTS: In the Popular Risk Score project (n = 2556), median time from blood collection to genotyping result was 4:04 h. In the Popular Genetics study (n = 1038), median time from randomization to genotyping result was 2:24 h. CONCLUSION: CYP2C19 genotyping is feasible in everyday clinical practice, both in the acute and non-acute settings.
AIM: A tailored antiplatelet strategy based on CYP2C19 genotype may reduce atherothrombotic and bleeding events. We describe our experience with CYP2C19 genotyping, using on-site TaqMan or Spartan genotyping or shipment to a central laboratory. METHODOLOGY: Data from two ongoing projects were used: Popular Risk Score project (non-urgent percutaneous coronary intervention patients) and the Popular Genetics study (ST-segment elevation myocardial infarctionpatients). For both projects, the time to genotyping result was calculated. RESULTS: In the Popular Risk Score project (n = 2556), median time from blood collection to genotyping result was 4:04 h. In the Popular Genetics study (n = 1038), median time from randomization to genotyping result was 2:24 h. CONCLUSION:CYP2C19 genotyping is feasible in everyday clinical practice, both in the acute and non-acute settings.
Authors: John T Brandt; Christopher D Payne; Stephen D Wiviott; Govinda Weerakkody; Nagy A Farid; David S Small; Joseph A Jakubowski; Hideo Naganuma; Kenneth J Winters Journal: Am Heart J Date: 2007-01 Impact factor: 4.749
Authors: Mrudula S Borse; Olivia M Dong; Melissa J Polasek; Joel F Farley; George A Stouffer; Craig R Lee Journal: Pharmacogenomics Date: 2017-07-26 Impact factor: 2.533
Authors: Ankie M Harmsze; Jochem W van Werkum; Christian M Hackeng; Hendrik J T Ruven; Johannes C Kelder; Heleen J Bouman; Nicoline J Breet; Jurriën M Ten Berg; Olaf H Klungel; Anthonius de Boer; Vera H M Deneer Journal: Pharmacogenet Genomics Date: 2012-03 Impact factor: 2.089
Authors: Dirk Sibbing; Werner Koch; Daniela Gebhard; Tibor Schuster; Siegmund Braun; Julia Stegherr; Tanja Morath; Albert Schömig; Nicolas von Beckerath; Adnan Kastrati Journal: Circulation Date: 2010-01-18 Impact factor: 29.690
Authors: Alan R Shuldiner; Jeffrey R O'Connell; Kevin P Bliden; Amish Gandhi; Kathleen Ryan; Richard B Horenstein; Coleen M Damcott; Ruth Pakyz; Udaya S Tantry; Quince Gibson; Toni I Pollin; Wendy Post; Afshin Parsa; Braxton D Mitchell; Nauder Faraday; William Herzog; Paul A Gurbel Journal: JAMA Date: 2009-08-26 Impact factor: 56.272
Authors: S A Scott; K Sangkuhl; C M Stein; J-S Hulot; J L Mega; D M Roden; T E Klein; M S Sabatine; J A Johnson; A R Shuldiner Journal: Clin Pharmacol Ther Date: 2013-05-22 Impact factor: 6.875
Authors: Borja Ibanez; Stefan James; Stefan Agewall; Manuel J Antunes; Chiara Bucciarelli-Ducci; Héctor Bueno; Alida L P Caforio; Filippo Crea; John A Goudevenos; Sigrun Halvorsen; Gerhard Hindricks; Adnan Kastrati; Mattie J Lenzen; Eva Prescott; Marco Roffi; Marco Valgimigli; Christoph Varenhorst; Pascal Vranckx; Petr Widimský Journal: Eur Heart J Date: 2018-01-07 Impact factor: 29.983
Authors: Larisa H Cavallari; Craig R Lee; Amber L Beitelshees; Rhonda M Cooper-DeHoff; Julio D Duarte; Deepak Voora; Stephen E Kimmel; Caitrin W McDonough; Yan Gong; Chintan V Dave; Victoria M Pratt; Tameka D Alestock; R David Anderson; Jorge Alsip; Amer K Ardati; Brigitta C Brott; Lawrence Brown; Supatat Chumnumwat; Michael J Clare-Salzler; James C Coons; Joshua C Denny; Chrisly Dillon; Amanda R Elsey; Issam S Hamadeh; Shuko Harada; William B Hillegass; Lindsay Hines; Richard B Horenstein; Lucius A Howell; Linda J B Jeng; Mark D Kelemen; Yee Ming Lee; Oyunbileg Magvanjav; May Montasser; David R Nelson; Edith A Nutescu; Devon C Nwaba; Ruth E Pakyz; Kathleen Palmer; Josh F Peterson; Toni I Pollin; Alison H Quinn; Shawn W Robinson; Jamie Schub; Todd C Skaar; D Max Smith; Vindhya B Sriramoju; Petr Starostik; Tomasz P Stys; James M Stevenson; Nicholas Varunok; Mark R Vesely; Dyson T Wake; Karen E Weck; Kristin W Weitzel; Russell A Wilke; James Willig; Richard Y Zhao; Rolf P Kreutz; George A Stouffer; Philip E Empey; Nita A Limdi; Alan R Shuldiner; Almut G Winterstein; Julie A Johnson Journal: JACC Cardiovasc Interv Date: 2017-11-01 Impact factor: 11.195
Authors: B A L M Deiman; P A L Tonino; K Kouhestani; C E M Schrover; V Scharnhorst; L R C Dekker; N H J Pijls Journal: Neth Heart J Date: 2016-10 Impact factor: 2.380
Authors: Shu Huang; Seonkyeong Yang; Shirly Ly; Ryan H Yoo; Wei-Hsuan Lo-Ciganic; Michael T Eadon; Titus Schleyer; Elizabeth Whipple; Khoa Anh Nguyen Journal: Eur J Clin Pharmacol Date: 2022-06-03 Impact factor: 3.064
Authors: Axel Rosengart; Malie K Collins; Philipp Hendrix; Ryley Uber; Melissa Sartori; Abhi Jain; Jennifer Mao; Oded Goren; Clemens M Schirmer; Christoph J Griessenauer Journal: Interv Neuroradiol Date: 2021-02-04 Impact factor: 1.764
Authors: Francesco Franchi; Fabiana Rollini; Jose Rivas; Andrea Rivas; Malhar Agarwal; Maryuri Briceno; Mustafa Wali; Ahmed Nawaz; Gabriel Silva; Zubair Shaikh; Naji Maailiki; Latonya Been; Andres M Pineda; Siva Suryadevara; Daniel Soffer; Martin M Zenni; Theodore A Bass; Dominick J Angiolillo Journal: JACC Basic Transl Sci Date: 2020-03-25
Authors: Shefali Setia Verma; Thomas O Bergmeijer; Li Gong; Jean-Luc Reny; Joshua P Lewis; Braxton D Mitchell; Dimitrios Alexopoulos; Daniel Aradi; Russ B Altman; Kevin Bliden; Yuki Bradford; Gianluca Campo; Kiyuk Chang; John H Cleator; Jean-Pierre Déry; Nadia P Dridi; Israel Fernandez-Cadenas; Pierre Fontana; Meinrad Gawaz; Tobias Geisler; Gian Franco Gensini; Betti Giusti; Paul A Gurbel; Willibald Hochholzer; Lene Holmvang; Eun-Young Kim; Ho-Sook Kim; Rossella Marcucci; Joan Montaner; Joshua D Backman; Ruth E Pakyz; Dan M Roden; Elke Schaeffeler; Matthias Schwab; Jae Gook Shin; Jolanta M Siller-Matula; Jurriën M Ten Berg; Dietmar Trenk; Marco Valgimigli; John Wallace; Ming-Shien Wen; Michiaki Kubo; Ming Ta Michael Lee; Ryan Whaley; Stefan Winter; Teri E Klein; Alan R Shuldiner; Marylyn D Ritchie Journal: Clin Pharmacol Ther Date: 2020-07-09 Impact factor: 6.875
Authors: Senthil Packiasabapathy; Blessed W Aruldhas; Pengyue Zhang; Brian R Overholser; Sara K Quinney; Senthilkumar Sadhasivam Journal: Pharmacogenomics Date: 2021-06-08 Impact factor: 2.533